Radikal Prostatektomi Yapılan Hasta Verilerinin Partin Tabloları İle Uyumluluğunun Araştırılması

Amaç: Bu çalışmada kliniğimizde radikal prostatektomi operasyonu geçiren prostat kanseri Pca hastalarının preoperatif ve postoperatif verilerinin Partin Tabloları ile uyumluluğunu değerlendirmeyi amaçladık. Gereç ve Yöntem: Pca nedeni ile radikal retropubik prostatektomi yapılan ortalama yaşları 66 47-75 olan 152 hasta çalışmaya dahil edilmiştir. Hastaların preoperatif klinik evreleri, biyopsi Gleason skorları ve total PSA değerleri kaydedilmiştir. Operasyonda çıkarılan pelvik lenf nodları, mikrometastatik kanser varlığı için mikroskopik olarak incelenmiştir. Operasyonda çıkarılan spesimen prostat ve veziküla seminalis histolojik inceleme için hazırlanmıştır. Partin Tablosunun kliniğimizdeki hasta grubu verileri ile ilişkisi Receiver Operating Characteristics ROC analizi ile değerlendirildi. Bulgular: T1c ve T2a hastalıkta patoloji spesimeninde lenf nodu pozitifliği gözlenmemiştir. T1c hastalık % 64 organ sınırlı iken T2c hastalık % 27 oranında organ sınırlı olarak bulunmuştur. Gleason 6 olan grupta lenf nodu ve seminal vezikül pozitifliği bulunmamaktadır. Gleason 8-10 olan hastalarda organ dışı yayılım % 66 ve lenf nodu pozitifliği % 33’tür. Serum PSA seviyesi 0-2,5 arası hastalar tüm populasyonun % 4’ünü, 2,5- 4 arası olan hastalar % 10’unu ve 4,1-6,0 arası olanlar % 8’ini 6,1-10,0 arası olanlar % 28’ini, 10’un üzerinde olanlar % 50’sini oluşturmaktadır. Area Under Curve AUC değerleri ekstra kapsüler yayılım, seminal vezikül tutulumu ve lenf nodu tutulumu için sırası ile 0,674 p

Data Evaluation İn Patients Undergoing Radical Prostatectomy İn Terms Of Compatibility With Partin Tables

Aims: In this study, we aimed to evaluate the preoperative and postoperative data of patients with prostate cancer Pca who underwent radical prostatectomy operations in our clinic and to compare them with the Partin Tables. Materials and Methods: 152 patients with a mean age of 66 47-75 who underwent radical retropubic prostatectomy for Pca were included in the study. Patients’ preoperative clinical stages, biopsy Gleason scores and total PSA values were recorded. pelvic lymph nodes removed during the operation were examined microscopically for the presence of micrometastatic cancer. Operative specimen prostate and vesicular seminalis was prepared for pathological examination. The association of patient’s data with Partin Tables was assessed by Receiver Operating Characteristics ROC analysis. Results: In T1c and T2a stage, lymph node positivity was not observed in the pathology specimen. In T1c stage, organ confined disease was 64% whereas in T2c stage organ confined disease was 27%. There is no lymph node and seminal vesicle positivity in the Gleason 6 group. In patients with Gleason 8-10, extracapsular extension is 66% and lymph node positivity is 33%. In the entire population, patients having PSA levels 0-2.5, 2.5-4 and 6.1-10.0 were 4%,10% and 8% respectively. Patients with PSA levels between 4.1- 6.0 were 28%, and those over 10 make up 50%. The Area Under Curve AUC values were 0.674 p

___

  • 1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2017. CA Cancer J Clin 2017; 67: 7–30.
  • 2. Murphy G, Haider M, Ghai S, et al. The expanding role of MRI in prostate cancer. AJR Am J Roentgenol 2013;201(6):1229–1238
  • 3. Karakiewicz PI, Bhojani N, Capitanio U, et al. External validation of the updated Partin tables in a cohort of North American men. The Journal of urology. 2008; 180:898–902.
  • 4. Ying Huang, Sumit Isharwal, Alexander Haese, et al. Prediction of patient-specific risk and percentile cohort risk of pathological stage outcome using continuous PSA measurement, Clinical Stage and biopsy Gleason score BJU Int. 2011 May; 107(10): 1562–1569.
  • 5. Ackerman DA, Barry JM, Wicklund RA,et al. Analysis of risk factors associated with prostate cancer extension to the surgical margine and pelvic node metastasis at radical prostatectomy. J Urol. 1993;150:1845-1850.
  • 6. Kleer E, Larson-Keller JJ, Zincke H, Oesterling JE. Ability of preoperative serum prostate specific antigen value to predict pathologic stage and DNA ploidy. Urology. 1993;41:207-216.
  • 7. Badalament RA, Miller MC, Peller PA, et al. An algorithm for predicting non-organ confined prostate cancer using the results obtained from sextant core biopsies with prostate-spesific antigen level. J Urol. 1996;156:1375-1380.
  • 8. Botswick DG, Qian J, Bergstralh E, et al. Prediction of capsuler perforation and seminal vesical invasion in prostate cancer. J Urol. 1996;155:1361-1367.
  • 9. Rogers E, Gurpinar T, Dillioglugil O, et al. The role of digital rectal examination, biopsy Gleason sum, and prostate-spesific antigen in selecting patient who require pelvic lymph node dissections for prostate cancer. Br. J Urol. 1996;78:419-425.
  • 10. Partin AW, Mangold LA, Lamm DM, Walsh PC, Epstein JI, Pearson JD. Contemporary update of prostate cancer staging nomograms (Partin Tables) for the new millennium. Urology. 2001;58:843–848.
  • 11. John B. Eifler, Zhaoyang Feng, Brian M. Lin, et al. An updated prostate cancer staging nomogram (Partin tables) based on cases from 2006 to 2011 BJU Int. 2013; 111(1)
  • 12. Lotan TL, Epstein JI. Clinical implications of changing definitions within the Gleason grading system. Nat Rev Urol. 2010; 7:136–142.
  • 13. Epstein JI. An update of the Gleason grading system. J Urol. 2010; 183:433–440.
  • 14. Eskicorapci SY, Karabulut E, Turkeri L, et al. Validation of 2001 Partin Tables in Turkey: A multicenter study. European Urology 2005;47:185-189.